Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/23494

Title:	Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.
Authors:	Cerrato, F Fernández-Suárez, M E Alonso, R Alonso, M Vázquez, C Pastor, O Mata, P Lasunción, M A Gómez-Coronado, D View more
Mesh:	Cells, Cultured Dose-Response Relationship, Drug Down-Regulation Hep G2 Cells Hepatocytes Humans Lipoproteins, LDL Lovastatin Lymphocytes Male Raloxifene Hydrochloride Receptors, LDL Selective Estrogen Receptor Modulators Structure-Activity Relationship Tamoxifen Toremifene View more
Issue Date:	Mar-2015
Citation:	Br. J. Pharmacol..2015 Mar;(172)5:1379-94
Abstract:	Treatment with selective oestrogen receptor modulators (SERMs) reduces low-density lipoprotein (LDL) cholesterol levels. We assessed the effect of tamoxifen, raloxifene and toremifene and their combinations with lovastatin on LDL receptor activity in lymphocytes from normolipidaemic and familial hypercholesterolaemic (FH) subjects, and human HepG2 hepatocytes and MOLT-4 lymphoblasts.
PMID:	25395200
URI:	https://hdl.handle.net/20.500.12530/23494
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC4337708.pdf		1.1 MB	Adobe PDF	View/Open